AD 221
Alternative Names: AD-221Latest Information Update: 27 Jul 2022
At a glance
- Originator Addpharma
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Hypercholesterolaemia
- Phase I Hyperlipidaemia
Most Recent Events
- 27 Jul 2022 700347566-Completed trial in kdm, added completion He
- 08 Jun 2022 Addpharma completes a phase III trial in Hypercholesterolaemia in South Korea (PO) (NCT05131997)
- 04 Mar 2022 Addpharma completes a phase I trial in Hyperlipidaemia (In volunteers) in South Korea (PO) (NCT05202405)